Institute for Biocomplexity and Informatics, Department of Biological Sciences, University of Calgary, Calgary, Alberta, Canada.
Curr Med Chem. 2010;17(30):3514-32. doi: 10.2174/092986710792927886.
Blockade of the human ether-a-go-go related gene 1 (hERG1) channel has been associated with an increased duration of ventricular repolarization, causing prolongation of the time interval between Q and T waves (long QT syndrome, or LQTS). LQTS may result in serious cardiovascular disorders such as tachyarrhythmia and sudden cardiac death. Diverse types of organic compounds bind to the wide intracellular cavity in the pore domain of hERG channels, leading to a full or partial blockade of ion current through the pore. The drug-induced blockade of the hERG-related component of the potassium current is thought to be a major reason for drug-induced arrhythmias in humans. Identification of specific interactions governing the high-affinity blockade of cardiac potassium (K-) channels is crucial both for the prevention of unintended ion channel block and for the design of ion channel modulators. A plethora of ligand- and receptor-based models of K-channels have been created to address these challenges. In this paper, we review the current state of knowledge regarding the structure-function relationship of hERG and discuss progress in the use of molecular modeling for developing both blockers and activators of hERG.
阻断人 ether-a-go-go 相关基因 1(hERG1)通道与心室复极时间延长有关,导致 Q 和 T 波之间的时间间隔延长(长 QT 综合征,或 LQTS)。LQTS 可能导致严重的心血管疾病,如心动过速和心源性猝死。多种有机化合物结合到 hERG 通道的孔域的宽细胞内腔中,导致通过孔的离子电流完全或部分阻断。药物诱导的 hERG 相关钾电流阻断被认为是人类药物诱导心律失常的主要原因。确定控制高亲和力心脏钾(K-)通道阻断的特定相互作用对于防止意外离子通道阻断和设计离子通道调节剂都至关重要。已经创建了大量基于配体和受体的 K-通道模型来解决这些挑战。在本文中,我们回顾了 hERG 的结构-功能关系的现有知识,并讨论了使用分子建模开发 hERG 阻断剂和激活剂的进展。